Excitatory amino acids and monoaminergic neurotransmitters in cerebrospinal fluid of acute ischemic stroke patients

Neurochemistry International

Volumn 56, Issue 8, 2010, Pages 865-870

  Brouns, Raf ^a,b,c   Van Hemelrijck, An ^d   Drinkenburg, Wilhelmus H ^d   Van Dam, Debby ^b   De Surgeloose, Didier ^a   De Deyn, Peter P ^a,b  

^a MIDDELHEIM HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d Neuroscience Research and Early Development   (Belgium)

Author keywords

Acute cerebral infarction; Amino acids; Cerebrospinal fluid; Neurotransmitters

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ASPARTIC ACID; DOPAMINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HOMOVANILLIC ACID; NEUROTRANSMITTER; NORADRENALIN; PROLINE; TAURINE;

AGED; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOPAMINE METABOLISM; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOGENIC MONOAMINES; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; BRAIN ISCHEMIA; DISEASE PROGRESSION; EXCITATORY AMINO ACIDS; FEMALE; HUMANS; MALE; NEUROTRANSMITTER AGENTS; SEVERITY OF ILLNESS INDEX; SPINAL PUNCTURE; STROKE; TIME;

EID: 77952882423     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.12.014     Document Type: Article

References (39)

1. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., Marsh E.E. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
2. Aliprandi A., Longoni M., Stanzani L., Tremolizzo L., Vaccaro M., Begni B., Galimberti G., Garofolo R., Ferrarese C. Increased plasma glutamate in stroke patients might be linked to altered platelet release and uptake. J. Cereb. Blood Flow Metab. 2005, 25:513-519.
3. Birschel P., Ellul J., Barer D. Progressing stroke: towards an internationally agreed definition. Cerebrovasc. Dis. 2004, 17:242-252.
4. Brouns R., De Deyn P.P. The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg. 2009, 111:483-495.
5. Brouns R., Heylen E., Sheorajpanday R., Willemse J.L., Kunnen J., De Surgeloose D., Hendriks D.F., De Deyn P.P. Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients. Clin. Neurol. Neurosurg. 2009, 111:165-170.
6. Brouns R., Marescau B., Possemiers I., Sheorajpanday R., De Deyn P.P. Dimethylarginine levels in cerebrospinal fluid of hyperacute ischemic stroke patients are associated with stroke severity. Neurochem. Res. 2009, 34:1642-1649.
7. Brouns R., Sheorajpanday R., Kunnen J., De Surgeloose D., De Deyn P.P. Clinical, biochemical and neuroimaging parameters after thrombolytic therapy predict long-term stroke outcome. Eur. Neurol. 2009, 62:9-15.
8. Brouns R., Sheorajpanday R., Wauters A., De Surgeloose D., Marien P., De Deyn P.P. Evaluation of lactate as a marker of metabolic stress and cause of secondary damage in acute ischemic stroke or TIA. Clin. Chim. Acta 2008, 397:27-31.
9. Brouns R., Van Den Bossche J., De Surgeloose D., Sheorajpanday R., De Deyn P.P. Clinical and biochemical diagnosis of small-vessel disease in acute ischemic stroke. J. Neurol. Sci. 2009, 285:185-190.
10. Brouns R., Heylen E., Willemse J.L., Sheorajpanday R., De Surgeloose D., Verkerk R., De Deyn P.P., Hendriks D.F. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb. Haemost. 2010, 8(1):75-80.
11. Brouns R., Wauters A., Van De Vijver G., De Surgeloose D., Sheorajpanday R., De Deyn P.P. Decrease of uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome. Clin. Chem. Lab. Med. 2010, 48(3):383-390.
12. Castellanos M., Sobrino T., Pedraza S., Moldes O., Pumar J.M., Silva Y., Serena J., Garcia-Gil M., Castillo J., Davalos A. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 2008, 71:1862-1868.
13. Castillo J., Davalos A., Naveiro J., Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996, 27:1060-1065.
14. Castillo J., Davalos A., Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 1997, 349:79-83.
15. Chen Z.L., Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997, 91:917-925.
16. Cohen S.A., Michaud D.P. Synthesis of a fluorescent derivatizing reagent, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, and its application for the analysis of hydrolysate amino acids via high-performance liquid chromatography. Anal. Biochem. 1993, 211:279-287.
17. Cote F., Fligny C., Fromes Y., Mallet J., Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 2004, 10:232-238.
18. Dambinova S.A., Khounteev G.A., Skoromets A.A. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke 2002, 33:1181-1182.
19. Davalos A., Castillo J., Serena J., Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 1997, 28:708-710.
20. Davalos A., Shuaib A., Wahlgren N.G. Neurotransmitters and pathophysiology of stroke: evidence for the release of glutamate and other transmitters/mediators in animals and humans. J. Stroke Cerebrovasc. Dis. 2000, 9:2-8.
21. Dhondt J.L. Difficulties in establishing reference intervals for special fluids: the example of 5-hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid. Clin. Chem. Lab. Med. 2004, 42:833-841.
22. Eskey C.J., Ogilvy C.S. Fluoroscopy-guided lumbar puncture: decreased frequency of traumatic tap and implications for the assessment of CT-negative acute subarachnoid hemorrhage. AJNR Am. J. Neuroradiol. 2001, 22:571-576.
23. Fujino K., Yoshitake T., Kehr J., Nohta H., Yamaguchi M. Simultaneous determination of 5-hydroxyindoles and catechols by high-performance liquid chromatography with fluorescence detection following derivatization with benzylamine and 1,2-diphenylethylenediamine. J. Chromatogr. A 2003, 1012:169-177.
24. Hachinski V., Shibuya M., Norris J.W., Hornykiewicz O. Cerebrospinal fluid homovanillic acid in cerebral infarction. J. Neural Transm. 1978, Suppl. 45-50.
25. Hazell A.S. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int. 2007, 50:941-953.
26. Jonnakuty C., Gragnoli C. What do we know about serotonin?. J. Cell. Physiol. 2008, 217:301-306.
27. Liu H., Sanuda-Pena M.C., Harvey-White J.D., Kalra S., Cohen S.A. Determination of submicromolar concentrations of neurotransmitter amino acids by fluorescence detection using a modification of the 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate method for amino acid analysis. J. Chromatogr. A 1998, 828:383-395.
28. Matsumoto K., Lo E.H., Pierce A.R., Halpern E.F., Newcomb R. Secondary elevation of extracellular neurotransmitter amino acids in the reperfusion phase following focal cerebral ischemia. J. Cereb. Blood Flow Metab. 1996, 16:114-124.
29. Meglic B., Kobal J., Osredkar J., Pogacnik T. Autonomic nervous system function in patients with acute brainstem stroke. Cerebrovasc. Dis. 2001, 11:2-8.
30. Nilsson T., Longmore J., Shaw D., Olesen I.J., Edvinsson L. Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br. J. Pharmacol. 1999, 128:1133-1140.
31. Olney J.W., Sharpe L.G. Brain lesions in an infant rhesus monkey treated with monsodium glutamate. Science 1969, 166:386-388.
32. Oto J., Suzue A., Inui D., Fukuta Y., Hosotsubo K., Torii M., Nagahiro S., Nishimura M. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J. Anesth. 2008, 22:207-212.
33. Serena J., Leira R., Castillo J., Pumar J.M., Castellanos M., Davalos A. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke 2001, 32:1154-1161.
34. Skvortsova V.I., Raevskii K.S., Kovalenko A.V., Kudrin V.S., Malikova L.A., Sokolov M.A., Alekseev A.A., Gusev E.I. Levels of neurotransmitter amino acids in the cerebrospinal fluid of patients with acute ischemic insult. Neurosci. Behav. Physiol. 2000, 30:491-495.
35. Strittmatter M., Meyer S., Fischer C., Georg T., Schmitz B. Location-dependent patterns in cardio-autonomic dysfunction in ischaemic stroke. Eur. Neurol. 2003, 50:30-38.
36. Sulter G., Steen C., De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999, 30:1538-1541.
37. Wood J.H. Neurochemical analysis of cerebrospinal fluid. Neurology 1980, 30:645-651.
38. Yoshitake T., Kehr J., Yoshitake S., Fujino K., Nohta H., Yamaguchi M. Determination of serotonin, noradrenaline, dopamine and their metabolites in rat brain extracts and microdialysis samples by column liquid chromatography with fluorescence detection following derivatization with benzylamine and 1,2-diphenylethylenediamine. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2004, 807:177-183.
39. Yoshitake T., Yoshitake S., Fujino K., Nohta H., Yamaguchi M., Kehr J. High-sensitive liquid chromatographic method for determination of neuronal release of serotonin, noradrenaline and dopamine monitored by microdialysis in the rat prefrontal cortex. J. Neurosci. Methods 2004, 140:163-168.